GLAUKOS Corp (GKOS) stock

GKOSNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 7/30219% above fair value

$245.72−0.31 (-0.13%)

Close on Nov 13, 2026Market cap $14.55BP/E –Yield –

Glaukos EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Glaukos's EV/EBITDA was 130.0× on Jul 29, 2022, against 424.6× a year earlier. Over the last 2 years it ranged from 97.1× to 749.8×, with a median of 296.3×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2022	Jul 29, 2022	130.0×	−489.5
2021	Dec 31, 2021	619.5×	+292.4
2018	Apr 30, 2018	327.1×	+28.9
2017	Dec 29, 2017	298.1×	+115.5
2016	Dec 30, 2016	182.6×	–

Where these numbers come from

Parsed from the XBRL in Glaukos's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is GKOS.

Compare: GKOS vs OFIX · GKOS vs SGHT · GKOS vs NVCR · GKOS vs BVS · GKOS vs ATEC

Revenue growth46.9% · median 12.9%

Gross margin64.8% · median 71.3%

Operating margin-25.5% · median -3.6%

Net margin-24.6% · median -10.3%

Company	Revenue	Growth
ATEC	$839.72M	+15.3%
OFIX	$835.41M	+2.1%
NVCR	$725.39M	+12.9%
GKOS	$690.33M	+46.9%
BVS	$585.64M	+3.9%
SGHT	$88.39M	+16.2%

Company

Next earnings (est.): Feb 16, 2027, after close
Exchange: NYSE
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 1,094
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1192448

Advertisement
300 × 250

See a number that looks wrong?

Glaukos EV/EBITDA

EV/EBITDA at the end of each year

More Glaukos figures